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2SUMMARY
The major protocol features of the immature rat uterotrophic assay have been evaluated using 
a range of reference chemicals. The protocol variables considered include the selection of the 
test species and route of chemical administration, the age of the test animals, the maintenance 
diet used and the specificity of the assay for estrogens.  It is concluded that three daily oral 
???????????????????????????????????????????????old rats, followed by determination of absolute 
uterus weights on the fourth day, provides a  sensitive and toxicologically relevant in vivo 
estrogenicity assay. Rats are favoured over mice for reasons of toxicological practice, but the 
choice of test species is probably not a critical protocol variable, as evidenced by the similar 
sensitivity of rats and mice to the uterotrophic activity of methoxychlor. Vaginal opening is 
??????????????????????????????????????????????????????????????????????????????????????????????????
chemicals to reduce or abolish the uterotrophic response of estradiol is suggested to provide a 
useful extension of the uterotrophic assay fo???????????????????????????????????????????
The results of a series of studies on the environmental estrogen nonylphenol (NP), and its 
?????????????????????????????????????????????????ng of the aliphatic sidechain is important 
for activity. 17 ???????????????????????????????????similar activity to estradiol in the 
uterotrophic assay, and is suggested to represent the ‘parent’ estrogen of NP. Benzoylation of 
?????????????????????????????????????????????r uterotrophic activity, in contrast to the 
enhancing effect of benzoylation on estradiol. 
Selected chemicals shown to be active in the immature rat uterotrophic assay were also 
evaluated in an in vitro yeast human estrogen receptor transactivation assay.  Most of the 
chemicals gave similar qualitative responses to those seen in the uterotrophic assay, and the 
detection of the estrogen methoxychlor by the yeast assay evidenced a degree of intrinsic 
metabolic competence. However, the assay had a reduced ability (compared to rodents) to 
hydrolyse the benzoate ester of estradiol, and the estrogenic benzoate derivative of NP was 
not active  in the yeast assay. These last results indicate that current metabolic deficiencies of 
in vitro estrogenicity assays will limit the value of negative data for the immediate future.  
The results described illustrate the intrinsic complexity of evaluating chemicals for estrogenic 
activities and confirm the need for rigorous attention to experimental design and criteria for 
assessing estrogenic activity. 
3INTRODUCTION
There is concern that some natural and synthetic chemicals have the potential to disturb 
normal sexual differentiation/development in animals and humans (Colborn and Clement, 
1992; McLachlan,  1993; McLachlan and Korach, 1995).  The ability of  some chemicals to 
elicit an estrogenic response in intact organisms forms one of the primary mechanisms by 
which such adverse effects could be produced (McLachlan and Korach, 1995).  One of the 
most extensively used assays for estrogenic activity is the rodent uterotrophic assay in which 
the ability of chemicals to stimulate uterine growth is monitored (Reel et al., 1996; O’Connor 
et al., 1996). There are a variety of protocols described for this assay, including the use of 
rats or mice; immature, hypophysectomized or ovariectomized animals, and the use of oral or 
subcutaneous routes of chemical administration. Given that most toxicity studies are 
currently conducted in rats, using the oral route of administration, we decided to evaluate the 
utility of the immature rat uterotrophic assay, using the oral route of chemical administration, 
as an in vivo assay for estrogenic activity. An associated objective was to  discern the critical 
features of the assay protocol.
Having confirmed the practicality of the immature rat uterotrophic assay it was used to study 
a range of reference hormonally active chemicals and to elucidate the chemical basis for the 
estrogenic activity reported for branched chain ???????????????????????????????????????????????
relationship between estrogenic activities observed in vitro, and those observed in vivo, some 
of the chemicals found positive in the uterotrophic assay were evaluated in the yeast human 
estrogen receptor (hER) transactivation assay described by Routledge and Sumpter (1996). 
MATERIALS AND METHODS 
Chemicals
Estradiol (E2; for chemical structures, see Scheme 1), ethinyl estradiol (EE), cyproterone  
acetate (CPA), methoxychlor  (MC; 98%), corn oil and arachis oil were obtained from Sigma 
(Poole, Dorset, UK). Estradiol benzoate (E2B) was obtained from Intervet (Cambridge, UK) 
as a solution in arachis oil (peanut oil). Coumestrol was obtained from Apin Chemicals  
(Abingdon, Oxfordshire, UK) and ICI 182,780 was a gift from Dr A Wakeling, Zeneca 
Pharmaceuticals (Alderley Park, Macclesfield ???????????????????????s obtained from two 
?????????????????????????????????????????????? Dorset, UK; 85% para isomers: NP(F)] 
?????????????????????????????????????????????s, USA; 94.2%: NP(S)]. NMR analysis of these 
??????????????????????????????????????????????????????????????????????????????????????
(nNP; 98%) was obtained from Lancaster synthesis (Morecambe, Lancashire, UK). The 
benzoate ester of NP(F), (NPB), was prepared by  standard benzoylation of the parent phenol 
(NP; Fluka). The structural integrity of the oily product was confirmed by NMR spectroscopy 
and elemental analysis. The benzoate ester of nNP (nNPB) was prepared by benzoylation of 
the parent phenol (nNP; source as above). ???????????????????????????????????????????o.
NMR and mass spectroscopy confirmed its structure and elemental analysis indicated that it 
??????????????????????????????????????????????????? ?????? ??????????????????????2]
was synthesized from estrone by the method described by Francois and Levisalles (1968). 
??????????????????????????????????????????????????????????o?????????????????????????????????
??????????o].  NMR and mass spectroscopy confirmed its structure and elemental analysis 
indicated that it contained 1/10 molecule of water. The corresponding benzoate derivative, 
??????????????????? ????????? ????????????????????????????? ?????????? ????????2B], was 
prepared by a standard benzoylation reaction. The product was recrystallized from 
??????????? ???????? ???? ???? ??????? ??????????? ?????????? ??? ???????o.  NMR, mass 
4spectroscopy and elemental analysis confirmed the structure and purity of the product. The 
???????????????????????????????????????????? ??????????????????????
diphenol; 99%] was a gift from MD Shelby, originally supplied by Cedra Corp., Austin, 
Texas, USA. 
Animals
???????????????????????????????????????????d, except where indicated otherwise) with body 
?????????????????????????????????????????????ng unit at Zeneca, Alderley Park. Immature 
Alderley Park Swiss Albino mice were obtaine?????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????????????????
was controlled and a 12h/12h light dark cycle was maintained. Animals were weaned on 
Harlan Teklad TRM diet (Harlan UK, Biceste??????????????????????????????????????????
maintained on pelleted PCD diet (Special Diet Services Ltd, Witham, Essex, UK) from 21 days 
onwards. Diet and water were available ad libitum. A range of additional diets were used in the 
rat dietary study, as described in the legend to Figure 9. Rat and mouse No.3 Breeding diet 
(R&M No.3), rat and mouse No.1 maintenance diet (R&M No.1) and casein diet (Super Casein 
batch RHM 92/117) were also obtained from Special Diet Services Ltd. All animals were 
acclimatized for 24h  before being dosed. 
Uterotrophic assays
The protocol for the uterotrophic assays was based on  that described by Wakeling et al.,
(1991).  Animals were dosed by either oral  gavage or subcutaneous (sc) injection. Test 
agents were dissolved or homogeneously suspended in arachis oil (except where indicated 
otherwise). The dosing volume for both routes of exposure was 5ml/kg body weight, except 
for the assays of coumestrol where a dosing volume of 10ml/kg was used. Animals received 3 
daily doses of the test compound and were killed by an overdose of halothane 24h after the 
final dose. The dose levels shown in the Figures are the daily dose levels. Vaginal opening 
(or otherwise) was recorded at the time of death. Uteri were excised, trimmed free of fat, 
pierced and blotted to remove excess fluid. The body of the uterus was cut just above its 
junction with the cervix and at the junction of the  uterine horns with the ovaries. The uterus 
was then weighed (wet weight). Uterine dry weight was also determined by drying the uteri 
at 70o???????????????????????????????????? et al., 1988). Dose levels were usually selected 
based on previous findings for estradiol, and in the case of those chemicals giving positive 
uterotrophic responses, the maximum tolerated dose (MTD) was probably not achieved. The 
top dose level of NP evaluated (285 mg/kg) was the MTD (data not shown). The analogs of 
NP were evaluated to this same top dose level. The top dose level of cyproterone acetate 
?????????????????????????????????????????????????????????????????????????
E2 ,or E2B, was used as a positive control agent in all of the studies, and each study was 
accompanied by a vehicle (negative) control group. Uterus wet weights are shown in the 
Figures, but uterus dry weights and uterus weight/body weight data were derived routinely 
and are discussed in the text. Generally, five animals per exposure group were employed, but 
this number was increased in some cases (see Figures) . 
Yeast assays
The yeast assay for estrogenic activity of chemicals, as described by Routledge and Sumpter 
(1996), has the DNA sequence of hER incorporated into the yeast genome. The molecular 
construct was designed to allow the activated? ????????? ??? ????? ??? ?????????????????????
sequences contained within a strong promoter region of an expression plasmid. When an 
active ligand binds to the estrogen receptor a lacZ reporter gene expresses the enzyme ?
galactosidase, which itself is quantitated using a chromogenic substrate. The methods used 
5were exactly as described earlier (Routledge and Sumpter, 1996).  Briefly, the test chemicals 
were dissolved in ethanol and added to 96 well plastic plates at the concentrations shown in 
Figure 15. The ethanol was allowed to evaporate before the addition of medium containing 
the yeast . The plates were incubated at 32  for 4 days and quantitated in terms of the 
absorbance of wells at 540 nm. Vehicle and estradiol controls accompanied each experiment, 
and representative data are shown. 
RESULTS AND DISCUSSION 
The results and discussion are presented in relation to the three topics evaluated in this study. 
Chemical structures are shown in Scheme 1. 
Critical protocol features of the uterotrophic assay
Estradiol benzoate (E2??????????????????????????????????crease in uterus weights in animals 
????????????????????????????????????????????????27 days at the start of the experiment had 
developed uteri and failed to respond further to the estrogenic challenge (Figure 1). Vaginal 
opening showed the same trend. The uterus we???????????????????????????????????????????
days at the end of the experiment were identical (Figure 1) despite a 20% difference in body 
weight at termination (data not shown).  These observations indicate that uterotrophic assays 
????????????????????????????????????????????????absolute uterus weight is probably a better 
index of uterine growth than the uterus/body weight index (see later for extension of the latter 
point).
Comparisons of the oral and sc routes of administration of the three established estrogens 
estradiol (E2 ), estradiol benzoate (E2??????????????????????????????????????????????????????????
E2 is more active in the uterotrophic assay when injected subcutaneously, but a similar 
maximal effect can be achieved following oral ?????????????????????????????????????????????
2). Based on these combined results, oral administration of 400 g/kg of the endogenous 
estrogen E2 was adopted as the standard positive control agent for the uterotrophic assay.   
The relationship between uterus wet weights, uterus wet weights relative to body weight, and 
uterus dry weights was essentially constant for all of the animals in the present study, and 
representative data for animals exposed to E2 are shown in Table 1. Uterus wet weights 
expressed relative to body weights are  subject ?????????????????????????????????????????????
(Ashby et al., 1997c), as illustrated by the slightly larger uterus/body weight ratio for animals 
exposed to the highest s.c. dose of  E2 , an effect dependant upon a small reduction in body 
weight for these animals (Table 1). We decided to regard absolute uterus wet weights as the 
primary assay parameter, with recourse to the determination of uterus dry weights in cases 
where it was considered necessary to confirm that a weak uterotrophic assay response was 
not due totally to increased water imbibation (c.f. such a suggestion; Evans et al., 1996).
The enhanced sensitivity of the uterotrophic assay to E2 when using sc injection, as opposed 
to oral administration, was also observed for both E2????????????????????????????????????
cutaneously administered  EE was the most potent estrogen encountered in the present study, 
showing trophic activity at 0.5 g/kg. The choice of route of administration for chemical 
studies will be influenced by the purpose for which the data are to be used. Oral 
administration is generally employed in chemical toxicity studies to be employed for human 
risk assessments, and it seems reasonable to stay with this route for routine toxicity studies. 
In some cases, such as when the shape of the dose response relationship is the critical issue, it 
may be appropriate to employ parenteral administration, but it would be inappropriate to use 
such routes routinely, especially if the only justification for that is that these routes have been 
6used historically. The specificity of the uterotrophic assay for estrogens was indicated by the 
???????????????????????????????????????????????????????????????????????????????????????????????
(Neumann, 1977;  Figure 5). 
The observation that premature vaginal opening appears to be a less sensitive marker of 
estrogenic activity than does the stimulation of uterine growth (Reel et a.,l 1996) has been 
?????????????????????????????????????????????In particular, premature vaginal opening does 
not always  parallel increases in uterine weight. For example, at doses giving approximately 
equivalent uterotrophic effects, orally administered E2 and EE produced premature vaginal 
?????????????????????????????????????????????????did not. To date, none of our control rats 
has had an open vagina at the time of th?? ????????????? ?????? ???????????? ???? ????????
nonetheless, some chemicals produce a clear uterotrophic effect in the absence of vaginal 
opening (see coumestrol, later herein). This indicates that while premature vaginal opening 
can strengthen the classification of an agent as an estrogen, it cannot be taken as a definitive 
requirement.  
The uterotrophic response produced by E2????????????????????????????????????????????????????
estrogen receptor antagonist ICI 182,780 (Wakeling and Valcaccia, 1983) when the latter was 
administered concomitantly with each dose of E2? ???????? ???? ????? ?????????? ????? ?????
estrogens can be detected using the uterotrophic assay by the simple expedient of challenging 
the assay positive control agent with the test chemical. Animals exposed to ICI 182,780, with 
or without E2, gave uterus weights that were decreased by ~50% when compared to 
concurrent control values. This led us to evaluate whether either the test vehicle, or the test 
diet, contained estrogenic contaminants. First, we evaluated whether the arachis oil vehicle 
was itself weakly estrogenic, some vegetable oils being known to contain phytoestrogens 
(Gunstone et al., 1994). The data shown in Figure 7 confirm that there was no difference in 
the uterus weights of untreated, arachis oil treated, or distilled water treated rats.  In each 
case, ICI 182,780  gave an approximately 50% reduction in uterus weights compared to 
concurrent controls. This indicated either that low levels of endogenous estrogens, or dietary 
phytoestrogens, were responsible for the elevated control uterus weights. The uterotrophic 
activity of the phytoestrogen coumestrol (Markarevich et al., 1995) (Figure 8) confirmed that 
estrogenic dietary contaminants have the potential to influence control uterus weights in 
uterotrophic assays. The data shown in Figure 9 confirmed that dietary estrogens were the 
probable reason why our control uterus weights could be reduced by administration of ICI 
182,780.  Based on these data, the R&M no.3 / R&M no.1 diet combination was adopted for 
routine use with the assay.  However, the experiments discussed in this paper were conducted 
before that change of diet occurred, thus the relatively high control uterus weights observed 
herein. Overall, the data shown in Figure 9 underline that diet should be considered as an 
important variable in any endocrine disruption assay, and that care should be taken to specify 
its source and constitution. 
The rat was selected as the primary test species for the present studies. However, the mouse 
has been used equally in the past, and the general sensitivity and utility of the mouse 
uterotrophic assay was recently confirmed by Shelby et al. (1996). One of the xenobiotic 
estrogens evaluated by Shelby et al. , methoxychlor (MC), was found to be inactive in the 
two in vitro estrogenicity assays employed,  probably because of the inability of these 
systems to remove the methyl groups of MC to yield the active diphenolic estrogenic species 
(Bulger et al. 1978). In fact, Shelby et al. (1996) demonstrated the latter diphenol to be 
estrogenic in vitro. In contrast, these authors  reported MC to be uterotrophic to the mouse 
?????????????????????????. The data shown in Figure 10 reveal that MC shows similar 
uterotrophic activity in the rat and the mous??? ?????? ??????? ????? ??? ??????????????
7administration. Shelby et al. (1996) expressed their uterotrophic assay data corrected for  
body weight, and when the mouse data shown in Figure 10 are similarly corrected, MC is 
found to have given a positive response of similar ????????????????????????????????????????????
increase in uterus weights over concurrent control levels, at 500 mg/kg MC).  These limited 
data for MC suggest that the choice of test species and route of chemical administration may 
only lead to quantitative, rather than qualitative, differences in uterotrophic assay outcomes.  
However, qualitatively  different test results will inevitably emerge for chemicals that are 
differentially absorbed and/or differentially metabolized in different test species.  The choice 
of test species and route of administration for the uterotrophic assay should be kept under 
review as new data accumulate.
Structural basis of the estrogenicity of nonylphenol
???????????????????????????????????????????????????????????????????????????????????????????
isomers. The commercial material is known to possess estrogenic properties (Soto et al.,
1995; Routledge and Sumpter, 1997), and these have been suggested to arise due to the 
structural similarity to E2 of one or more of the isomers of NP. Warhurst (1994) has 
suggested one particular isomer of NP as being the most likely to bind to and activate the 
estrogen receptor (Scheme 1). This isomer happens to be similar in structure to octylphenol, a 
related compound that contains only one isomer (as shown in Scheme 1) and which is active 
as an estrogen in vitro (Routledge and Sumpter, 1997) and in vivo (Bicknell et al., 1995).
Recently, Sanborn (1996) erroneously associated the estrogenic properties of commercial NP 
with the linear aliphatic sidechain isomer nNP, a compound which is not estrogenic (see 
below). Sanborn (1996) also suggested that hydroxylation of the aliphatic sidechain of 
nonylphenols (shown for nNP in Scheme 1) was required to complete their structural 
alignment with E2 . However, that suggestion is not supported by the observation that NP, per
se, competes with E2 in bindings to isolated cytosolic estrogen receptors, i.e., without the 
need for prior metabolic transformation (Soto et al., 1995; White et al., 1994). 
As recently reported by Lee and Lee (1996), NP ?????????????????????????????????????????????
immature rat uterotrophic assay (Figure 11). This response was abolished by 
???????????????????????????????????????????antagonist ICI 182,780, thereby confirming that 
the effect was mediated via the estrogen receptor (Figure 11).  Similar levels of uterotrophic 
activity were observed for the two different sa???????????????????????????????????????
(Figure 12). The inactivity of the straight chain analog of NP (nNP;  Figure 12) was 
supported by its inactivity in the yeast assay (see below). The inactivity of nNP favors the 
????????????????????????????????????????????????in NP is important to the interaction of the 
chemical with the estrogen receptor (Routledge and Sumpter, 1997; Warhurst, 1994). It is 
interesting to note the weak assay responses for NP shown in Figure 12. The reproducibility 
of these weak effects, and the observation of cases of vaginal opening among the test 
animals, establish uterotrophic activity in these cases; nonetheless, these data indicate the 
urgent  need to agree criteria for discerning activity in the uterotrophic assay (Ashby et al.,
1997c).
It was noted earlier that E2B is a more potent estrogen in the uterotrophic assay than is E2
itself (Figures 2 and 3). This enhancement of activity is probably caused by a combination of 
factors, such as reduced conjugative excretion of the free phenol (E2) by protection of its 
acidic phenol substituent, and the enhanced lipophilicity of the benzoate (E2B) in comparison 
to the parent phenol (E2).  It therefore became of interest to evaluate if the benzoate 
derivative of NP (NPB) would be more potent than NP itself, and in particular, if the 
benzoate derivative (nNPB) of the inactive st??????????????????????????????????????????????
in the uterotrophic assay.  The data shown in Figure 13 demonstrate that these two benzoates 
8were of similar activity to the parent phenols; equally as positive, and negative, respectively. 
These rather surprising findings indicate that th???????????????????????????????????????????????
estradiol cannot be generalized, and that nNP seems to be devoid of intrinsic estrogenic 
activity.
The suggestion that the estrogenic activity of NP is due to the ability of some of its 
constituent isomers to mimic estradiol in binding to the estrogen receptor (Routledge and 
Sumpter, 1997; Warhurst, 1994) indicates that the 17 ???????? ??????????? ??? ??????????
?????????2) should represent the progenitor ‘est???????????????????????????????????2 is 
reported to be uterotrophic to hypophysectomised rats (Huggins and Jensen, 1955) and to be 
able to compete with estradiol in binding to isolated estrogen receptors (Fanchenko et al.,
?????????????????????????????????????????????????2????????????????????????????????????????2
was uterotrophic to immature rats (Figure 14), showing a slightly higher minimum detection 
level than E2  and a more flattened dose response relationship (Figures 3 and 14).  As 
????????????????????????????????????????????????????????????2??????????2B) showed similar 
activity in the uterotrophic assay to ?????????????????????????????????????2; Figure 14). It 
therefore appears that the suggestion that one or more of the branched chain isomers of NP is 
able to mimic estradiol in binding to the estrogen receptor is a valid and useful observation, 
???? ????? ????????2 ? ?? ???? ?????????? ????? ??? ???? ????????????????? ???????????
However, the suggestion that the aliphatic sidechain of NP requires to be hydroxylated before 
NP acquires estrogenic activity (Sanborn,  1996) seems to be unlikely. 
Relative sensitivity of the yeast  estrogenicity assay and the uterotrophic assay
In vitro assays will be of particular value in cases where a lead chemical showing estrogenic 
activity is shown to be positive in the in vitro assay, and where the activity of structural 
analogs of the lead chemical are the subject of study. The yeast hER assay described by 
Routledge and Sumpter (1996), has shown sensitivity to a wide range of chemical classes of 
estrogens, and the assay has intrinsic metabolic competence, as evidenced by its ability to 
detect as positive the estrogen MC (Figure 15; Ashby et al., 1997b), despite the inability of 
some other in vitro assays to detect it (Shelby et al., 1996). This attribute of the yeast assay is 
probably due to the enhanced metabolic competence of growing yeast cells and their 
presumed ability to demethylate MC to the active estrogenic diphenol derivative 
?????????????????????et al., 1996; Bulger et al., 1978). As expected, the yeast assay was 
more sensitive to the ultimate estrogenic species???????????????????????????????????????????
to MC itself (Figure 15). 
????????????????????????????2 ???????????????????????2 (Figure 15). This 
reduced activity is consistent with? ???? ????????? ??????????? ??? ????????2 and E2 in the 
??????????????????????????????????????????????????????????????????????????2 in vitro and in
vivo has implications for the derivation of structure activity relationships among xenobiotic 
estrogens (Katzenellenbogen, 1995; Waller et al.?????????????????????????????????????????
hydroxy and the 17 ?????????????????????????????????????????? considered to be necessary for 
estrogenic activity. 
The yeast assay is less sensitive to E2B than it is to E2 (Figure 15). This is in contrast to the 
marginally enhanced activity of E2B, compared to E2 , in the uterotrophic assay (Figures 2 
and 3). This indicates that the yeast assay is?????????????????????????????????????????????????
group present in E2B, but that this is not completed under the conditions of the test. As 
observed with the uterotrophic assay, the yeast assay found the two different samples of NP 
to be of similar estrogenic activity, and nNP to be inactive (Figure 15). In surprising contrast 
to in the uterotrophic assay, the benzoate derivative of NP (NPB) was inactive in the yeast 
9assay (Figure 13). This suggests that the yeast cells possess only selective esterase activity, 
being able to hydrolyse partially the benzoate ester of E2B, while being unable to hydrolyse 
the benzoate ester of NPB. 
In summary, the yeast estrogenicity assay has demonstrated high general sensitivity, and a 
level of metabolic competence, in the present studies. A potential weakness of this (and 
probably of all other in vitro assays) is highlighted by the failure of the yeast assay to detect 
as positive the in vivo estrogen NPB. That failure is perhaps reflected quantitatively by the 
reduced sensitivity of the assay to E2B in comparison to E2.  Although the problem posed by 
the inadequate metabolic competence of the current in vitro estrogenicity assays must be 
solved before they can achieve their true potential (Ashby et al., 1997a; Ashby, 1997), the 
partial metabolic competence of the present yeast assay confirms it as a valuable screening 
test.
CONCLUSIONS
The results described here illustrate the intrinsic complexity of evaluating chemicals for 
estrogenic activities. Suitable detection systems exist, but the manner in which they are  
deployed can influence the toxicological value of the data derived. It is recommended that 
when designing experiments in this area of toxicology it is important consider the purposes 
for which the test data will be used. This will influence practical decisions, such as choice of 
in vitro or in vivo assays, and the choice of dose levels and route of chemical administration 
in rodent studies. At the practical level, there is an urgent need to agree criteria for assessing 
the activity of chemicals in the available estrogenicity assays, and to enhance the metabolic 
competence of the currently available  in vitro assays.
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Table 1.  The effect of 17 ???????????????????????????????????????????????????????????????
administered by either oral gavage or subcutaneous (sc) injection. Group sizes are as 
described in Figure 2.
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94
20 62.8
4.0
39.0
7.4
116 0.624  
 0.13 
117 6.99  
1.16
104
40 60.9
3.6
38.3
4.3
114 0.630  
 0.07 
119 7.66  
0.84
114
100 60.8
3.4
68.1
17.5
202 1.120  
 0.29 
211 12.15  
 3.20 
182
200 60.7
3.2
70.9
14.9
210 1.165  
 0.22 
219 13.05  
 3.70 
195
400 63.2
5.4
101.7
16.7
302 1.614  
 0.26 
304 19.37  
 2.36 
289
sc
injection
0 63.8
4.8
38.2
7.3
100 0.597  
 0.10 
100 7.09  
 1.13 
100
0.5 66.0
3.2
40.5
3.2
106 0.616  
 0.06 
103 7.83  
0.65
111
1 63.4
3.7
42.3
7.0
111 0.666  
 0.08 
112 8.10  
1.29
114
2 65.3
4.8
43.9
5.8
115 0.670  
 0.04 
112 8.34  
1.01
118
5 63.1
5.2
86.4
9.8
226 1.368  
 0.11 
229 15.00  
 2.21 
212
10 62.7
3.1
95.4
17.0
250 1.519  
 0.25 
254 16.92
 2.31 
239
20 61.8
3.6
86.4
13.4
226 1.482  
 0.12 
248 15.73  
 2.32 
222
40 63.1
2.9
84.9
6.0
222 1.348  
 0.09 
226 15.61
 1.28 
220
200 60.6
3.6
89.0
11.8
235 1.486  
 0.20 
249 16.45  
 1.65 
232
400 61.9
4.5
101.2
14.5
265 1.628  
 0.16 
273 17.98  
 2.31 
254
020
40
60
80
100
120
140
160
180
0 10 0 10 0 10
???????????????????????????????????????????????????????????
??????????????????????????????????????
????????????????????????????
5
5
5 5
55
?
?
?
?
?
?
?
?
?
2 2 ??w
e
14
?
?
?
?
?
?
?
?
?
?
U
FIGURE 1???????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????
???????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????
5
????????????
??????????????
????
0
20
40
60
80
100
120
140
0.1 1 10 100 1000 10000 100000 1000000
oral gavage
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
FIGURE 2???????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????????????????????????????????
?????????????????????????????????????????????
sc injection
?????????????????
2
10 2
?
5
10 5
5
5 5
5
5
15
5
5
5
15
25
18
??
020
40
60
80
100
120
140
0.1 1 10 100 1000 10000 100000
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?????????????????????????
oral gavage
sc injection
????????????
??????????????
????
FIGURE 3??????????????????????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????????????????????????????????????
??????????????????N ???????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????
?
4
5
?
15
5
5
5
5
30
5
5
2
4
?
5
5
5
20
N
5
0
20
40
60
80
100
120
140
0.01 0.1 1 10 100 1000 10000 100000
???????????????????
15
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
oral gavage
sc injection
N?
N
4?
N
?
?
????????????
??????????????
????
5
15
5
5 10
5
5
20
10 5 5
5
FIGURE 4???????????????????????????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????????????????????????????????
????????? ??????????????????N???????????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????
020
40
60
80
100
120
140
?? ??? ??? ??? ???? ????
?????????????????????
5 555
5
5 55
?
?
4
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
? ?2
FIGURE 5???????????????????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????2 ?????
????????????????????????????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????????????
0
20
40
60
80
100
120
0 2 4 6 8 10
???????????????????????????????
16
?
?
??
?
??
?
??
?
?
?
?
?
?
?
?
?
?
?
?
10
5
5 5 5
5
5
????????????
??????????????
???
?
2
FIGURE 6????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????
??
40
??
??
?
?
5
10
10
020
40
60
80
100
120
??? ?? ?? ??
17
U
?
?
?
?
??
?
??
?
?
?
?
?
?
?
?
?
??
?
5 5
5
3
7
20
??????????????????
? ?2
?
FIGURE 8??????????????????????????????????????????????????????????????????????????????
?????????????????????????????2 ????????????????????????????????????????????
???????????????????????????????????????????????????????????????? ??????????????????????????????
???????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????????????????????????????
20
??
??
??
40
??
w
?
?
?
?
?
?
?
?
?
?
?
?
?
?
??????
??
???
??
18
????
??????????
? ??? ? ?? ??? ??? ???? ???
0
20
40
60
80
100
120
140
?2 ?2 2
?????????? ????????
10
5
3
10
3
5
5
5
5
5
5
5
5
FIGURE 10?????????????????????????????????????????????????????????????????????????????????????????????????????????
????????????????????????????????????2???????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????????????????????????????????????????????????
?????????????????????????????????????????
????????????????????
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
??
??
1
?
4
4
18
80
100
120 7
?
?
?
?
e
?0
20
40
60
80
100
120
140
0.1 1 10 100 1000 10000 100000
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
4
?
?
2
20
5
5
10
5
5 5
5
20
55
10
5
55 5
5
20
????????????
??????????????
????
??????????????????
19
FIGURE 14?????????????????????????????????????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
????????????????????????? ???2????? ??????????????2 ?????????????????????????????????????????????
??????????????????????????????????????????????????????2 2???????????????????????????????????
??????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
???????????
2
???????????
?????
?
??
??
?
??
?
?
?
?
?
?
?
?
?
?
?
2
???
?
??
?2 ?2B
????????2
??????
??????
20
FIGURE 11???????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????????????????2
??????????????????????????????????????????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????????????????????
0
10
20
??
40
??
60
??
80
??
100
???? ?? ??? ??? ???????????????????????
?????????????????????
?????????????
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
5
5
5
5
?
55
5
? ?2
?
21
0
20
40
60
80
100
120
? ?NP NP???
IV
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
0
20
40
60
80
100
120
? ??? ?????
II
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
0
20
40
60
80
100
120
? ?2 ??? ?????
I
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
0
20
40
60
80
100
120
? ??? ?????
III
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
5
?2
?2 ?2
4
2
2
1
4
2 4
?
5 5
5
5
5 5
5 5
5
5
5
5
5 5
5
FIGURE 12???????????????????????????????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????????????????????????????????
????????????2????????????????????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????? ?????????????????
????????????????????????????
